April 6 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX :
* FDA INDICATES PARADIGM PHASE 2B ENDPOINTS ARE APPROPRIATE FOR PHASE 3 CLINICAL TRIAL
April 6 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX :
* FDA INDICATES PARADIGM PHASE 2B ENDPOINTS ARE APPROPRIATE FOR PHASE 3 CLINICAL TRIAL